RT Journal Article
SR Electronic
T1 Competing Risks in Patients with Primary Prevention Implantable Cardioverters Defibrillators: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.16.20248369
DO 10.1101/2020.12.16.20248369
A1 Waks, Jonathan W.
A1 Haq, Kazi T.
A1 Tompkins, Christine
A1 Rogers, Albert J.
A1 Ehdaie, Ashkan
A1 Bender, Aron
A1 Minnier, Jessica
A1 Dalouk, Khidir
A1 Howell, Stacey
A1 Peiris, Achille
A1 Raitt, Merritt
A1 Narayan, Sanjiv M.
A1 Chugh, Sumeet S.
A1 Tereshchenko, Larisa G.
YR 2020
UL http://medrxiv.org/content/early/2020/12/29/2020.12.16.20248369.abstract
AB Background Global electrical heterogeneity (GEH) is associated with sudden cardiac death in the general population.Objective To investigate whether GEH is associated with sustained ventricular tachycardia (VT)/ventricular fibrillation (VF) leading to appropriate implantable cardioverter-defibrillator (ICD) therapies in systolic heart failure (HF) patients with primary prevention ICDs.Methods We conducted a multicenter retrospective cohort study. GEH was measured by spatial ventricular gradient (SVG) direction and magnitude, QRS-T angle, and sum absolute QRST integral (SAIQRST) on pre-implant 12-lead ECGs. Survival analysis using cause-specific hazard functions compared the strength of associations with two competing outcomes: sustained VT/VF leading to appropriate ICD therapies and all-cause death without appropriate ICD therapies.Results We analyzed data from 2,668 patients (age 63±12y; 23% female; 78% white; 43% nonischemic cardiomyopathy (NICM); left ventricular ejection fraction 28±11% from 6 academic medical centers). After adjustment for demographic, clinical, device, and traditional ECG characteristics, SVG elevation (Hazard Ratio (HR) per 1 standard deviation (SD) 1.14 (95% CI 1.04-1.25); P=0.004), SVG azimuth (HR 1.12(1.01-1.24); P=0.039); SVG magnitude (HR per 1 SD 0.75 (0.66-0.85); P<0.0001), and QRS-T angle (HR per 1 SD 1.21 (95% CI 1.08-1.36); P=0.001) were associated with appropriate ICD therapies. The SVG azimuth was also associated with a lower competing risk of death (Pdifference=0.007): HR 0.91(0.82-1.02); P=0.095. SAIQRST had different associations in ischemic [HR 1.29(1.04-1.60)] and NICM [HR 0.78(0.62-0.96); Pinteraction=0.022].Conclusion In patients with primary prevention ICDs, GEH is independently associated with appropriate ICD therapies. The SVG vector points in distinctly different directions in patients with two competing outcomes.Clinical Trial Registration URL:www.clinicaltrials.gov Unique identifier: NCT03210883.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialURL:www.clinicaltrials.gov Unique identifier: NCT03210883Clinical Protocols https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556174/ Funding StatementThis study was funded through the AHA Grant-In-Aid #17GRNT33670428 (LGT) and partially HL118277 (LGT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The multicenter study has been approved by the OHSU Institutional Review Board (IRB). In addition, each participating center obtained local IRB approval prior to participating.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be available through the National Heart, Lung, and Blood Institute Biological Specimen and Data Repository Information Coordinating Center (BioLINCC) after the publication of this manuscript (planning submission). The open-source MATLAB (MathWorks, Natick, MA, USA) code for ECG analysis is provided at https://physionet.org/physiotools/geh and https://github.com/Tereshchenkolab/Origin. Statistical analysis code is provided at https://github.com/Tereshchenkolab/statistics. https://physionet.org/physiotools/geh https://github.com/Tereshchenkolab/Origin https://github.com/Tereshchenkolab/statistics CMcardiomyopathyLVEFleft ventricular ejection fractionSCDsudden cardiac deathICDimplantable cardioverter-defibrillatorNYHANew York Heart AssociationHFheart failureICMischemic/infarct-related cardiomyopathyNICMnonischemic cardiomyopathyGEHglobal electrical heterogeneitySVGspatial ventricular gradientCRT-Dcardiac resynchronization therapy defibrillatorPVCpremature ventricular complexSAIQRSTsum absolute QRST integralVMQTiQT integral on vector magnitude signalNIDnumber of intervals to detect